About Alexander Koglin
Alex Koglin joined Mercury Bio’s board in 2024. Mercury Bio develops medicines for Parkinson’s and Alzheimer’s disease that deliver therapeutic material inside affected cells.
Earlier, he earned advanced degrees from Goethe University and held a Human Frontier Science Program fellowship at Harvard Medical School. He later worked at Los Alamos National Laboratory as a research scientist and J. Robert Oppenheimer Fellow. He left in 2015 to help launch Nature’s Toolbox, known as NTx. There, he served as co-founder, president, and chief scientific officer. He led research, managed three rounds totaling more than $61 million, and secured support from BARDA and DARPA. He also established research partnerships with pharmaceutical companies. He left NTx in February 2024 after nearly nine years.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Alexander Koglin in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Alexander Koglin works with at each company, as listed on that company's latest Form D.
